Search results for "Autoinflammation"

showing 9 items of 9 documents

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adeniti…

2023

ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction.Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 ± 7.00 months in the period b…

International Registry PFAPA syndrome Streptococcus salivarius K12 autoinflammatory disease probiotic prophylaxis tonsillitisSettore MED/38 - Pediatria Generale E SpecialisticaAutoinflammationGeneral MedicineHuman medicinePFAPA syndromeFrontiers in Medicine
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A S…

2020

This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p<0.05…

0301 basic medicinemyalgiaMaleAbdominal painSettore MED/16 - REUMATOLOGIATNFRSF1AGene mutationGastroenterology0302 clinical medicinePathologyMedicineRB1-214PericarditisChildPrognosisPenetranceInflamacióFamilial Mediterranean FeverAIDA networkEstudi de casosReceptors Tumor Necrosis Factor Type IChild PreschoolAutoinflammationFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdolescentGenotypetumor necrosis factorImmunologyContext (language use)Asymptomatic03 medical and health sciencesYoung AdultInternal medicineAnimalsHumansRetrospective Studies030203 arthritis & rheumatologyInflammationbusiness.industrytumor necrosis factor TRAPS AIDA networkTumor Necrosis Factor-alphaInfantTRAPSCell BiologyMyalgiaBiological productmedicine.disease030104 developmental biologyMutationCase studiesbusinessKidney diseaseMediators of Inflammation
researchProduct

Histopathological progression of hidradenitis suppurativa/acne inversa

2021

It is generally acknowledged that the first morphological change of hidradenitis suppurativa/acne inversa (HS/AI) consists of infundibular plugging of the folliculosebaceous apocrine apparatus, which is followed by acute and chronic inflammation, cysts with sinus formation, and fibrosis. Alternatively, it has been hypothesized that HS/AI is primarily a neutrophilic autoinflammatory disease and that the follicular plugging typical of this disease is secondary to inflammation.To review the sequence of the changes that mark the disease development, we have performed a histopathologic study on the surgical material from a series of axillary and inguinal/perineal cases.The histologic material fr…

Early lesionPathologymedicine.medical_specialty030209 endocrinology & metabolism030204 cardiovascular system & hematologyInner root sheathPathogenesis03 medical and health sciences0302 clinical medicineFibrosismedicineHumansHidradenitis suppurativaPathologicalAcneSkinInflammationbusiness.industryApocrineDevelopmental disturbanceGeneral Medicinemedicine.diseaseImmunohistochemistryHidradenitis SuppurativaMutationAutoinflammationImmunohistochemistryUninvolved skinbusinessHair FollicleWiener Medizinische Wochenschrift
researchProduct

Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry

2023

AbstractThis study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (…

Settore MED/16 - REUMATOLOGIABehçet's diseaseBehçet’s syndromeArthritisArthritis; Behçet’s syndrome; International registry; Pediatric rheumatology; Rare diseasesRare diseasesSettore MED/38 - Pediatria Generale E SpecialisticaArthritis Behçet’s syndrome International registry Pediatric rheumatology Rare diseasesInternational registryEmergency MedicineInternal MedicineAutoinflammationPediatric rheumatologyArthriti
researchProduct

Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases

2022

ObjectiveThis paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected by Undifferentiated Systemic AutoInflammatory Diseases (USAIDs).MethodsThis is an electronic registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is designed to obtain standardized information for real-life research. The instrument is endowed with flexibility, and it could change over time according to the scientific acquisitions an…

RegistrySettore MED/16 - REUMATOLOGIAprecision medicinerare diseasesGeneral Medicinepersonalized medicineautoinflammatory diseasesInternational RegistrySettore MED/38 - Pediatria Generale E Specialisticaautoinflammatory diseaseAutoinflammationHuman medicineInternational Registry; autoinflammatory diseases; personalized medicine; precision medicine; rare diseasesautoinflammatory diseases; International Registry; personalized medicine; precision medicine; rare diseases
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

2015

Autoinflammatory disorders (AIDs) are a novel class of diseases elicited by mutations in genes regulating the homeostasis of innate immune complexes, named inflammasomes, which lead to uncontrolled oversecretion of the proinflammatory cytokine interleukin-1β. Protean inflammatory symptoms are variably associated with periodic fever, depicting multiple specific conditions. Childhood is usually the lifetime in which most hereditary AIDs start, though still a relevant number of patients may experience a delayed disease onset and receive a definite diagnosis during adulthood. As a major referral laboratory for patients with recurrent fevers, we have tested samples from 787 patients in the perio…

Adultmedicine.medical_specialtyReferralProinflammatory cytokineDiagnosis DifferentialRheumatologyAcquired immunodeficiency syndrome (AIDS)Internal medicinePeriodic feverMedicineHumansAge FactorChildGenetic disorderInnate immune systembusiness.industryHereditary Autoinflammatory DiseasesAge FactorsGeneral Medicinemedicine.diseaseAdulthoodInterleukin-1βRheumatologyImmunity InnateHereditary Autoinflammatory DiseasePeriodic feverSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyRecurrent feverImmunologyAutoinflammationbusinessAutoinflammatory DisordersHuman
researchProduct